Wave Life Sciences to Present at the 29th Annual Credit Suisse Healthcare Conference

Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) is set to present at the 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 5:00 p.m. ET. Dr. Paul Bolno, President and CEO, will deliver the presentation. A live webcast can be accessed through the company's Investor Relations page, with a recording available for 60 days post-event. Wave Life Sciences focuses on developing innovative genetic treatments using its proprietary PRISM platform to design and optimize stereopure oligonucleotides, addressing various genetically defined diseases.

News Market Reaction – WVE

-0.80%

-0.80% Session move

In the trading session that priced this news, WVE declined 0.80%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 29^th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2020 at 5:00 p.m. ET.

A live webcast of the presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 60 days following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contacts:
Graham Morrell
781-686-9600
gmorrell@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

FAQ

What is Wave Life Sciences presenting at the Credit Suisse Healthcare Conference 2020?

Wave Life Sciences Ltd. is presenting at the 29th Annual Credit Suisse Healthcare Conference on November 11, 2020.

Who is presenting for Wave Life Sciences at the conference?

Dr. Paul Bolno, President and CEO of Wave Life Sciences, will present at the conference.

How can I watch the Wave Life Sciences presentation live?

The presentation can be streamed live on the Investor Relations page of Wave Life Sciences' website.

Where can I find a replay of the Wave Life Sciences conference presentation?

A replay of the presentation will be available on the company’s Investor Relations site for 60 days after the event.

What is the focus of Wave Life Sciences as a company?

Wave Life Sciences is focused on developing genetic medicines for treating genetically defined diseases.